Inlet Private Wealth Reduces Bristol Myers Squibb Stake

Firm sells 9,600 shares of biopharmaceutical company's stock

Apr. 7, 2026 at 10:54am

Got story updates? Submit your updates here. ›

An extreme close-up of intricate financial machinery and equipment, conveying the tangible nature of banking and wealth management without depicting any literal currency or symbols.An institutional investor's portfolio adjustments reflect broader trends in the pharmaceutical industry as firms monitor the performance and prospects of major drug companies.Princeton Today

Inlet Private Wealth LLC, a financial advisory firm, reduced its stake in Bristol Myers Squibb Company (NYSE:BMY) by 25.7% during the fourth quarter of 2025. The firm now owns 27,806 shares of the biopharmaceutical company's stock, valued at $1.5 million.

Why it matters

This transaction reflects broader trends in the pharmaceutical industry, as investors closely monitor the performance and pipeline of major drug companies like Bristol Myers Squibb. Institutional investors' portfolio adjustments can provide insights into market sentiment and the perceived growth prospects of individual firms.

The details

Inlet Private Wealth sold 9,600 shares of Bristol Myers Squibb during the fourth quarter, reducing its total holdings to 27,806 shares. The firm's position was previously valued at $1.8 million, indicating a decrease of around $300,000 in the value of its Bristol Myers Squibb investment.

  • Inlet Private Wealth's stake reduction occurred during the fourth quarter of 2025.
  • The firm's holdings in Bristol Myers Squibb were valued at $1.5 million at the end of the reporting period.

The players

Inlet Private Wealth LLC

A financial advisory firm that manages investments for private clients.

Bristol Myers Squibb Company

A global biopharmaceutical company focused on developing and delivering medicines for serious diseases, with a strong emphasis on cancer and immune-mediated conditions.

Got photos? Submit your photos here. ›

The takeaway

This transaction highlights the ongoing scrutiny and portfolio adjustments made by institutional investors in the pharmaceutical sector, as they assess the growth potential and risk profiles of major drug companies like Bristol Myers Squibb.